Press Releases
Carnival Corporation and Global Maritime Partners Complete Simulator Tests Shaping the Future of Navigation
Bridge ‑ simulator tests brought together ports, hydrographic offices, pilots and mariners to help define how next-generation IHO S-100 navigation data will be used at the helm of navigation's next era Video of the IHO S-100 Test Bed and Sea Trial in Confined Waters can be viewed and downloaded here . ALMERE, Netherlands, April 20, 2026 /PRNewswire/ -- As the maritime industry prepares for the next generation of digital navigation, Carnival Corporation & plc (NYSE/LSE: CCL; NYSE: CUK), through its Center for Simulator Maritime Training (CSMART), has completed a series of bridge simulator tests evaluating S‑100 navigational data in collaboration with international hydrographic offices and industry partners under the International Hydrographic Organization's (IHO) S‑100 Test Bed and Sea Trial in Confined Waters...
QNX and NVIDIA Deepen Collaboration to Advance Safety-Critical Edge AI Across Robotics, Medical, and Industrial Systems
QNX OS for Safety 8.0 and NVIDIA IGX Thor deliver a unified platform for real‑time control, functional safety, and AI at the industrial edge HANNOVER, DE / ACCESS Newswire / April 20, 2026 / At Hannover Messe, QNX, a division of BlackBerry Limited (NYSE:BB)(TSX:BB) today announced an expansion of its collaboration with NVIDIA to enable developers to build and deploy next‑generation, safety‑critical edge AI systems on NVIDIA IGX Thor. The expanded relationship sees QNX OS for Safety 8.0 integrated with NVIDIA IGX Thor and Halos Safety Stack, combining QNX's proven, deterministic real‑time operating system with NVIDIA's functional safety platform to support regulated, AI‑enabled systems across robotics, medical technologies, industrial applications and more...
Schneider Electric and Deloitte collaborate to drive AI-enabled digital transformation across industrial operations
Schneider Electric and Deloitte announce collaboration to modernize end-to-end processes across their business operations and unlock new opportunities
Equinor ASA: Buy-back of shares to share programmes for employees
Please see below information about transactions made under the buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR) for shares to be used in the share-based incentive programmes for employees and management.
InterContinental Hotels Group PLC Announces Transaction in Own Shares - April 20
Purchase of own shares LONDON, UK / ACCESS Newswire / April 20, 2026 / The Company announces that on 17 April 2026 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 8 May 2025 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 17 February 2026, as announced on 17 February 2026...
OSB GROUP PLC - Transaction in Own Shares
OSB GROUP PLC ISIN: GB00BLDRH360 20 April 2026 LEI number: 213800ZBKL9BHSL2K459 OSB GROUP PLC (the “Company”) Share Buyback Programme – Transactions in Own Shares The Company announces that, for the period from 13 April 2026 to 17 April 2026, inclusive, it had purchased a total of 706,075 of its ordinary shares of £0.01 each (the "ordinary shares") on the London Stock Exchange, CBOE BXE, CBOE CXE and Aquis Exchange, through the Company's broker Jefferies International Limited as detailed below. The repurchased ordinary shares will be cancelled...
Genflow Biosciences PLC Announces Strategic Technology Collaboration
Genflow Biosciences Enters Strategic Technology Collaboration with Acuitas Therapeutics - Fully Funded, Non-Dilutive Access to World-Class LNP Delivery Platform LONDON, UK / ACCESS Newswire / April 20, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), a European biotechnology company focused on the development of gene therapies for age-related diseases, today announces that it has entered into a strategic technology collaboration with Acuitas Therapeutics ("Acuitas"), a globally recognised leader in lipid nanoparticle ("LNP") delivery systems whose technology has underpinned some of the most commercially successful mRNA therapeutic programmes brought to market to date. Strategic Significance The Board considers this collaboration to represent a material step forward in the advancement of the Company's SIRT6 platform...
Flow Traders appoints Frank Drouet as CEO Asia-Pacific to support regional expansion
Flow Traders appoints Frank Drouet as CEO Asia-Pacific to support regional expansion Amsterdam, the Netherlands — Flow Traders Ltd. (Euronext: FLOW) announces a leadership update in the Asia-Pacific (APAC) region. With immediate effect, Frank Drouet is appointed Chief Executive Officer Flow Traders APAC and joins the firm's Executive Committee (ExCo)...
Mowi ASA (OSE:MOWI): Q1 2026 Trading update
Harvest volumes Q1 2026 (1) Farming Norway 75.5 thousand tonnes Farming Scotland 20.5 thousand tonnes Farming Chile 21.0 thousand tonnes Farming Canada 8.0 thousand tonnes Farming Ireland 2.0 thousand tonnes Farming Faroes 3.0 thousand tonnes Farming Iceland (Arctic Fish) 6.0 thousand tonnes Total 136.0 thousand tonnes Harvest volumes of 136 thousand tonnes versus 108 thousand tonnes in Q1 2025 are record-high for a first quarter, equivalent to a growth of 26%. In connection with the presentation of the Q4 2025 results, Mowi guided a total harvest volume of 128k GWT for Q1 2026...
Prospera Energy Announces Slate of Industry Presentations and Conferences
Calgary, Alberta--(Newsfile Corp. - April 20, 2026) - Prospera Energy Inc. (TSXV: PEI) (OTC Pink: GXRFF) ("Prospera", "PEI", the "Company", or the "Corporation") is pleased to announce a slate of upcoming investor presentations, speaking engagements, and industry participation covering capital markets forums, technical conferences, and professional development events. The breadth of invitations reflects increasing industry recognition of Prospera's heavy oil reactivation strategy, disciplined operational execution, and positioning as a differentiated junior producer in Western Canada...
B2Gold Reports Update on Fire-Related Incident to the Crushing Circuit at the Goose Mine
VANCOUVER, British Columbia, April 19, 2026 (GLOBE NEWSWIRE) -- B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G) (“B2Gold” or the “Company”) announced today an update on the near-term operational plan related to the fire that occurred in certain areas of the crushing circuit at the Goose Mine in the evening of April 16, 2026, as described in B2Gold's news release on April 17, 2026...
Mitsubishi Electric to Launch Railway Energy Management Solution Proof of Concept for Krakow Tram Network in Poland
TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it will launch a proof of concept (PoC) project for a railway energy management solution (railway EMS) to be tested on the tram network in Krakow, Poland, beginning in April 2026. The project will combine Mitsubishi Electric's SerendieTM digital platform and energy storage systems (ESSs) for the efficient capture and use of surplus regenerative braking power during tram operations. Support for the project...
Leapmotor Selects QNX for D19 Premium Electric SUV, Production Starts April 2026
Centralized high‑performance controller built on QNX SDP 8.0 and QNX Hypervisor for Safety 8.0, consolidates digital cockpit and ADAS onto one holistic safety‑certified platform WATERLOO, ON / ACCESS Newswire / April 19, 2026 / QNX, a division of BlackBerry Limited (NYSE:BB)(TSX:BB) today announced that leading Chinese electric vehicle company, Leapmotor, has selected QNX technology to serve as the foundational software platform for its forthcoming premium electric SUV, the D19. Centralized Architecture for Next-Generation Experiences At the heart of the new D19 is a high‑performance central controller built on the QNX Software Development Platform 8.0 and QNX Hypervisor for Safety 8.0, enabling a unified architecture for advanced cockpit and ADAS experiences...
Humana, Inc. Data Breach: Edelson Lechtzin LLP Launches Investigation Into Exposure of Social Security Numbers, Medical Claims, and Patient Account Data
LOUISVILLE, Ky., April 19, 2026 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from the Humana, Inc. data breach.
First Challenger Assays Return Grades up to 170g/t Au
New zones of high-grade mineralisation identified in open pit walls HIGHLIGHTS 8,065m reverse circulation (RC) Resource upgrade drilling recently completed at Challenger 'Main', 'Challenger West' (CW) open pits, and 'Challenger South-Southwest' (CSSW) and 'Challenger 3' targets[1] Challenger's 'Main' open pit operated during 2002 - 2004; drilling has identified new high-grade mineralisation in the open pit's walls and extensions, where new assays include: [2] Hole ID Interval Including: CHB0140 9m @ 2.20 g/t Au from 97 metres 1m @ 6.63 g/t Au from 103 metres CHB0158 11m @ 5.67 g/t Au from 24 metres 10m @ 17.7 g/t Au from 40 metres 1m @ 50.9 g/t Au from 27 metres 1m @ 170.7 g/t Au from 43 metres CHB0159 14m @ 1.01 g/t Au from 19 metres 3m @ 4.72 g/t Au from 40 metres 3m @ 2.55 g/t Au from 22 metres 1m @ 11.8 g/t Au from 40 metres CHB0165 3m @ 6.85 g/t Au from 121 metres 1m @ 15.0 g/t Au from 121 metres Further assays pending for the CW open pit, and the CSSW and Challenger 3 open pit targets Challenger DFS underway targeting a viable, simplified 'baseline' Stage 1 operation to underwrite restart of CGM and maximise Challenger, Tarcoola, Wudinna and Tolmer development optionality ADELAIDE, AU / ACCESS Newswire / April 19, 2026 / Barton Gold Holdings Limited (ASX:BGD)(OTCQB:BGDFF)(FRA:BGD3) (Barton or Company) is pleased to announce initial assay results from recent drilling at its South Australian Challenger Gold Project (Challenger). Challenger is the site of the Company's fully permitted Central Gawler Mill (CGM)...
CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3)
SUZHOU, China, April 19, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas, today announced that the Company presented the latest preclinical data for three proprietary pipeline assets at the American Association for Cancer Research (AACR) Annual Meeting (from April 17 to 22), including CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), and CS5008 (DLL3/SSTR2 ADC). CStone's Proprietary ADC Technology Platform All three antibody-drug conjugates (ADCs) presented at AACR – CS5007 (EGFR/HER3 ADC), CS5006 (ITGB4 ADC), and CS5008 (DLL3/SSTR2 ADC) – are developed utilizing CStone's proprietary ADC technology platform, which incorporates the following core features: High Stability & Precise Payload Release: The platform utilizes CStone's proprietary CSL20 linker, a hydrophilic construct designed for enhanced stability in circulation...
Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting
ROCKVILLE, Md. and SUZHOU, China, April 19, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it will present four preclinical studies in poster format at the American Association for Cancer Research (AACR) 2026 Annual Meeting, held April 17 to 22, 2026 in San Diego, CA, USA...
Faraday Future Announces $45 Million in New Financing with a U.S. Institutional Investor to Strongly Support the Execution of Its EAI Robotics & EAI EV Business; Plans to Pursue Long-Term Strategic Cooperation with the Investor for Mutual Benefit
LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future,” “FF” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today announced that the Company has signed a $45 million financing agreement (the “Agreement”) with a U.S. institutional investor (the “Investor”), with the full amount received on the same day. The proceeds will significantly support the execution of the Company's EAI (Embodied AI) ecosystem strategy. Un...
Modular Medical Announces Pricing of $3.4 Million Registered Direct Offering of Common Stock
SAN DIEGO, CA / ACCESS Newswire / April 19, 2026 / Modular Medical, Inc. ("Modular Medical" or the "Company") (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, today announced the pricing of a registered direct offering (the "Offering") consisting of 750,000 shares of the Company's common stock at an offering price of $4.50 per share. The gross proceeds to the Company from the Offering are estimated to be approximately $3.4 million before deducting placement agent fees and other offering expenses...
SK hynix Begins Mass Production of 192GB SOCAMM2 'Setting a New Standard for AI Server Memory Performance'
- Mass production of 192GB high capacity products designed for the NVIDIA Vera Rubin platform - Maximizes power efficiency by featuring high density DRAM based on the latest 1cnm process - Company to closely collaborate with NVIDIA to solve bottlenecks in AI infrastructure and provide optimal performance SEOUL, South Korea, April 19, 2026 /PRNewswire/ -- SK hynix Inc. (or "the company", www.skhynix.com) announced today that it has begun mass production of the 192GB SOCAMM2, a next-generation memory module standard based on the 1cnm process (sixth-generation of the 10-nanometer technology) LPDDR5X low-power DRAM. SOCAMM2[1] is a module that adapts low-power memory – which was previously used mainly in mobile products like smartphones – for server environments...
SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock
IRVINE, Calif.--(BUSINESS WIRE)-- #Healthcare--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company's common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the unde...
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, announced new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) showing greater neurologic benefit versus standard of care (SoC) in Wilson disease patients with neurologic symptoms at baseline. The data will be presented today at the American Academy of Neurology (AAN) Annual Meeting 2026, taking place April 18-22, 2026...
Amplitude Research Reveals a Generational AI Trust Gap is Costing Australian Businesses
SYDNEY--(BUSINESS WIRE)--New research by Amplitude reveals generational AI trust gap among Australian businesses.
Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing platform Tumor regressions observed across various cancer models at low single ‑ digit mg/kg doses, with favorable tolerability (HNSTD 60 mg/kg) and low systemic levels of free payload (≤0.01% AUC) Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mid-2026 MORRISTOWN, N.J., April 19, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of new preclinical data across its ADC portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026, in San Diego, CA...
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
VANCOUVER, British Columbia and BOSTON, MA, April 19, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today presented positive data from the Phase 3 X-TOLE2 study highlighting the efficacy and safety of azetukalner in focal onset seizures (FOS) at the American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois. Xenon is also presenting data at the AAN meeting that reinforce the significant opportunity for azetukalner in epilepsy, including 48-month data from the ongoing X-TOLE open-label extension (OLE) study, as well as real-world data reinforcing the potential value that no-titration options like azetukalner would bring to epilepsy management. Azetukalner (AZK) is a novel, potent, KV7 potassium channel opener currently in clinical development for epilepsy and depression...
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
Sidus Space Announces Pricing of $58.5 Million Registered Direct Offering of Class A Common Stock
CAPE CANAVERAL, Fla., April 19, 2026 /PRNewswire/ -- Sidus Space, Inc. (Nasdaq: SIDU) ("Sidus" or the "Company"), an innovative space and defense technology company, today announced the pricing of a best-efforts registered direct offering of 13,453,700 shares of its Class A common stock (or pre-funded warrants ("Pre-funded Warrants") in lieu thereof) at an offering price of $4.35 per share (inclusive of the Pre-funded Warrant exercise price) for gross proceeds of approximately $58.5 million, before deducting the placement agent's fees and offering expenses...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Company announcement – No. 8 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April 19, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no...
Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2026
Company announcement – No. 7 / 2026 Zealand Pharma launches long-term incentive programs for Zealand Pharma's Board of Directors, Corporate Management and employees for 2026 Copenhagen, Denmark, April 19, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no.
AST SpaceMobile Addresses Today's Orbital Launch of BlueBird 7 on the New Glenn Launch Vehicle
MIDLAND, Texas--(BUSINESS WIRE)---- $ASTS #AST--AST SpaceMobile, Inc. ("AST SpaceMobile") (NASDAQ: ASTS), the company building the first and only space-based cellular broadband network accessible directly by everyday smartphones, designed for both commercial and government applications, addresses today's orbital launch of BlueBird 7 on the New Glenn launch vehicle. During the New Glenn 3 mission, BlueBird 7 was placed into a lower than planned orbit by the upper stage of the launch vehicle. While the satellit...
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) clinical data for zoldonrasib, an oral RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC). Results were highlighted in the official press program at the American Association for Cancer Research (AACR) Annual Meeting and will be featured in a plenary oral presentation today, April 19, 2026, at 1:30 p.m. PDT...
Elektros Inc. Advances Patented Multi-Port EV Charging Technology to Address Growing Global Demand (OTC Markets:ELEK)
SUNNY ISLES BEACH, FL / ACCESS Newswire / April 19, 2026 / Elektros Inc. (OTC:ELEK) today announced continued development of its patented multi-port electric vehicle (EV) charging system, designed to significantly improve charging efficiency, infrastructure utilization, and scalability as global EV adoption accelerates. The company's proprietary technology enables multiple electric vehicles to charge simultaneously from a single charging unit, addressing one of the most critical constraints in EV infrastructure: limited access and congestion at charging stations...
QXO to Acquire TopBuild for $17 Billion
GREENWICH, Conn. & DAYTONA BEACH, Fla.--(BUSINESS WIRE)--QXO, Inc. (NYSE: QXO) today announced that it has entered into a definitive agreement to acquire TopBuild Corp. (NYSE: BLD) (“TopBuild”) for approximately $17 billion, significantly expanding QXO's scale and capabilities across the building products value chain. The transaction is expected to be immediately and substantially accretive to the company's earnings. TopBuild is the largest distributor and installer of insulation and related bu...
Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass, April 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the presentation of new preclinical data across three posters at the American Association for Cancer Research (AACR) Annual Meeting 2026...
Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026
SAN FRANCISCO, April 19, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review 52-week topline results from the 16-week extension treatment period of the ongoing Phase 2b REZOLVE-AA clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for severe-to-very-severe alopecia areata on Monday, April 20, 2026 at 8:00 am ET / 5:00 am PT. Conference Call The results will be provided in a morning press release and presented during the webcast...
Harmonic Enables DIRECTV to Reimagine Nationwide DTH Service
Harmonic's Cloud-Native VOS Media Software Lowers Costs by Unifying Media Playout to Delivery on a Single Platform SAN JOSE, Calif., April 19, 2026 /PRNewswire/ -- Harmonic (NASDAQ: HLIT) today announced that DIRECTV is transforming its U.S. direct-to-home (DTH) video platform with Harmonic's VOS Media Software...
Challenge accepted: Schneider Electric helps industry turn toughest problems into competitive advantage
HANNOVER, Germany, April 19, 2026 (GLOBE NEWSWIRE) -- Industrial operations are under pressure from every direction. Energy costs are rising.
SeoulCeuticals Publishes First Official Layering Guide for Volufiline Snail Mucin Serum, Identifying Retinol Sequencing as the Cause of Preventable Irritation for Millions of Users
SeoulCeuticals published the first official layering protocol for its Ultra Snail + Volufiline Serum, identifying incorrect retinol sequencing as the primary cause of irritation and poor results. The protocol establishes snail mucin before retinol as the critical adjustment most users miss.
10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and Understood
Enables Whole-Transcriptome In Situ Spatial Biology with Single-Cell Sensitivity at Scale Debuts at AACR Annual Meeting 2026 with Data from Leading Research Institutions, Including the June Lab at the Perelman School of Medicine, University of Pennsylvania and German Cancer Research Institute (DKFZ) PLEASANTON, Calif., April 18, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced Atera, a new in situ spatial biology platform engineered to deliver whole-transcriptome spatial analysis with single-cell sensitivity at unprecedented scale...
Elektros Inc. Unveils Breakthrough Patent for Multi-Port EV Charging Technology
SUNNY ISLES BEACH, FL / ACCESS Newswire / April 18, 2026 / Elektros Inc. today announced the advancement of its patented multi-port charging assembly for electric vehicles, an innovation designed to enhance charging efficiency, accessibility, and scalability in the rapidly expanding electric mobility sector. The patented technology introduces a multi-port charging system capable of servicing multiple electric vehicles simultaneously from a single infrastructure point...
Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapies targeting the underlying causes of psychiatric and neurological disorders, today issued the following statement supporting the newly signed White House Executive Order aimed at accelerating research, development, and responsible access to innovative treatments for serious mental illness, including emerging psychedelic medi...
Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration's Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could h...
NASDAQ: SMCI Investors who lost over $100,000 with purchases made between April 2024 and March 2026 should contact the Shareholders Foundation in connection with Lawsuit
SAN DIEGO, April 18, 2026 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Super Micro Computer, Inc. (NASDAQ: SMCI) shares. Investors, who purchased shares of Super Micro Computer, Inc. (NASDAQ: SMCI) between April 30, 2024, and March 19, 2026, in excess of $100,000, have certain options and there are short and strict deadlines running...
Baron & Budd Finalizes $774 Million Settlement With Albertsons in Nationwide Opioid Litigation
DALLAS--(BUSINESS WIRE)--This week, the nationally recognized law firm Baron & Budd announced the finalization of a $774 million nationwide settlement agreement with retail pharmacy giant Albertsons Companies, Inc. Albertsons has agreed to the payout which will be distributed to states, counties, municipalities, and Native American tribes to resolve allegations concerning the company's role in the opioid epidemic. Baron & Budd's President and Managing Shareholder, Russell Budd, played a...
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months
Bragar Eagel & Squire, P.C. Reminds Eos Energy Enterprises, Inc. (NASDAQ:EOSE) Investors to Contact the Firm Regarding Their Rights Before May 5th
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Eos (EOSE) To Contact Him Directly To Discuss Their Options
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced new data from a preclinical study of ZL-1503, demonstrating that the company's internally developed IL-13/IL-31Rα bispecific antibody may lead to sustained suppression of intense pruritus (itch) and inflammation caused by atopic diseases. The findings, featured in a poster presentation at the IMMUNOLOGY2026 conference in Boston, MA, reinforce the potential of ZL-1503 to be a first-in-class t...
EUROPEAN WAX: Kaskela Law Seeks Additional Compensation for European Wax Center (EWCZ) Shareholders Subject to Buyout and Encourages Investors to Contact the Firm to Learn How to Participate
Philadelphia, Pennsylvania--(Newsfile Corp. - April 18, 2026) - On April 3, 2026, European Wax Center, Inc. (NASDAQ: EWCZ) ("European Wax") reported that it has scheduled a special meeting of stockholders to be held on May 7, 2026, during which it will ask its investors to vote to approve the $5.80 per share stockholder buyout proposal. As that meeting date has now been set, Kaskela Law alerts European Wax shareholders that they now only have a limited period of time – prior to the special meeting of stockholders – to act if they wish to preserve their legal rights and options with respect to buyout transaction...
CLEARWATER ANALYTICS: Kaskela Law Seeks Additional Compensation for Clearwater Analytics Holdings (CWAN) Shareholders Subject to Buyout and Encourages Investors to Contact the Firm to Learn How to Participate
Philadelphia, Pennsylvania--(Newsfile Corp. - April 18, 2026) - On April 8, 2026, Clearwater Analytics Holdings, Inc. (NYSE: CWAN) ("Clearwater") reported that it has scheduled a special meeting of stockholders to be held on May 6, 2026, during which it will ask its investors to vote to approve the $24.55 per share stockholder buyout proposal. As that meeting date has now been set, Kaskela Law alerts Clearwater shareholders that they now only have a limited period of time – prior to the special meeting of stockholders – to act if they wish to preserve their legal rights and options with respect to buyout transaction...
DUOL INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Duolingo
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Duolingo To Contact Him Directly To Discuss Their Options If you suffered significant losses in Duolingo stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 18, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Duolingo, Inc. ("Duolingo" or the "Company") (NASDAQ: DUOL)...
HUBG INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hub Group
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Hub Group To Contact Him Directly To Discuss Their Options If you suffered significant losses in Hub Group stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 18, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hub Group, Inc. ("Hub Group" or the "Company") (NASDAQ: HUBG)...
HELE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Helen of Troy
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Helen of Troy To Contact Him Directly To Discuss Their Options If you suffered significant losses in Helen of Troy stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - April 18, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Helen of Troy Limited ("Helen of Troy" or the "Company") (NASDAQ: HELE)...
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient population ADAPT SERON, OCULUS, and Jr study results build on VYVGART's approved gMG indication and show its potential as the first and only biologic therapy effective across MG subtypes ADHERE post hoc analysis supports earlier use of VYVGART in treatment-naïve CIDP patients, with 87.5% achieving early benefit April 18, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the presentation of new data for VYVGART (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) at the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago from April 18-22, 2026. Presentations will also highlight new data for adimanebart in congenital myasthenic syndromes (CMS) and argenx's broader neuromuscular pipeline, including Phase 3 programs evaluating empasiprubart in CIDP...
B2Gold Reports Fire-Related Incident to the Crushing Circuit at the Goose Mine
VANCOUVER, British Columbia, April 17, 2026 (GLOBE NEWSWIRE) -- B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G) (“B2Gold” or the “Company”) announced today that a fire occurred in certain areas of the crushing circuit at the Goose Mine in the evening on April 16, 2026. On-site emergency responders were deployed and immediately initiated response procedures, and the fire was fully extinguished. No injuries were reported, no medical treatment was required, and mining operations are continuing on plan. The Company has been in contact with the relevant regulatory authorities...
Crypto News: Pepeto Presale Fast Sell Out Stage Whilst Ethereum Price Prediction Reaches $7,500 By Standard Chartered
Dubai, UAE, April 17, 2026 (GLOBE NEWSWIRE) -- The Ethereum based token Pepeto just confirmed that its latest presale stage closed out in hours, a clear sign that buyer demand around the token is climbing sharply. That speed alone reveals how much belief now sits behind this project, and as the launch gets closer, early round buyers keep returning to add bigger positions every time. Each passing week makes it harder to ignore the idea that Pepeto could become the standout crypto news story of 2026...
CORRECTING and REPLACING Mountain Valley MD Announces Appointment of Advisors and Stock Option Grants
TORONTO--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: MOUNTAIN VALLEY MD ANNOUNCES APPOINTMENT OF ADVISORS AND STOCK OPTION GRANTS Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTC: MVMDF) announces that it is issuing this amended and updated news release to correct inadvertent errors in the biographical information of certain advisors previously announced in its news release issu...
Formation Metals Responds to OTC Markets Request on Recent Promotional Activity
VANCOUVER, BC / ACCESS Newswire / April 17, 2026 / Formation Metals Inc. ("Formation" or the "Company") (CSE:FOMO)(FSE:VF1)(OTCQB:FOMTF) announces that it has been requested by OTC Markets Group Inc. ("OTC Markets") to issue this statement regarding recent promotional activity concerning the Company's common shares traded on the OTCQB market. On April 16, 2026, OTC Markets informed the Company that it became aware of certain promotional activities concerning the Company and its common shares (each, a "Share"), including the distribution of digital marketing materials by Steller Media Group, LLC ("Stellar")...
Extreme Networks Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Extreme Networks, Inc. - EXTR
NEW YORK and NEW ORLEANS, April 17, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
Nexstar Media Group, Inc., Statement on Preliminary Injunction
IRVING, Texas--(BUSINESS WIRE)--Nexstar Media Group releases statement on the preliminary injunction issued in connection with the company's acquisition of TEGNA Inc.
Orthofix Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Orthofix Medical, Inc. - OFIX
NEW YORK and NEW ORLEANS, April 17, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
37 Capital Makes an Investment in SpendRight, Inc
Vancouver, British Columbia--(Newsfile Corp. - April 17, 2026) - 37 Capital Inc. (CSE: JJJ) ("37 Capital" or the "Company") announces that it has acquired for US $100,000 a 5% ownership in SpendRight, Inc., an arm's length US based company ("SpendRight"). SpendRight is developing a consumer-focused AI platform designed to help individuals spend more efficiently by surfacing the right deals at the right time and in the right place...
Québec Nickel Corp. Announces Closing of Private Placement
Vancouver, British Columbia--(Newsfile Corp. - April 17, 2026) - Québec Nickel Corp. (CSE: QNI) (FSE: 7lB0) (OTCQB: QNICF) ("QNI" or the "Company") announces that it has closed its previously announced (March 4, 2026) non-brokered private placement (the "Offering") for aggregate gross proceeds of $777,250. Pursuant to the Offering, the Company issued 3,109,000 units (the "Units") at a price of $0...
RedCloud Holdings Plc Receives Notice Regarding Minimum Bid Price Requirement
Ordinary shares will continue to trade on the Nasdaq Capital Market, and the Company's listing on such exchange is not affected by the receipt of the Notice Ordinary shares will continue to trade on the Nasdaq Capital Market, and the Company's listing on such exchange is not affected by the receipt of the Notice
Faraday Future Announces $45 Million New Financing; Plans to Hold Annual Meeting of Stockholders on May 22 to Seek Approval of Key Proposals Designed to Accelerate EAI Strategy Execution and Protect Stockholder Interests
LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future,” “FF” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today announced that it plans to hold the Annual Meeting of Stockholders (the “Annual Meeting”) on May 22, 2026, to seek approval for proposals aimed at supporting the Company's Global EAI strategic execution and long-term growth. The Company's Board of Directors (the “Board”) urges all stockholders to vot...
AI/ML Innovations Announces Completion of Share Issuance
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA TORONTO, ON / ACCESS Newswire / April 17, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FSE:42FB) is pleased to announce that it has completed its previously announced share for debt issuance with certain service providers of the Company pursuant to which the Company has issued an aggregate of 17,118,420 common shares (the "Subject Shares") at a deemed price of Cdn$0.05 per Subject Share in consideration of past services and satisfaction of outstanding indebtedness. The Subject Shares are subject to a statutory hold period expiring on August 18, 2026...
American Aires Provides Update on Liquidity Position, Strategic Review and Ongoing Litigation
Toronto, Ontario--(Newsfile Corp. - April 17, 2026) - American Aires Inc. (CSE: WIFI) (OTCQB: AAIRF) (the "Company") issues this update regarding its liquidity position, its ongoing strategic review, and its previously disclosed litigation. As previously disclosed, the Company is pursuing legal proceedings against certain former officers and related parties (the "Litigation") in connection with alleged misconduct and related matters...
Cashmere Valley Bank Announces Preliminary Results of Tender Offer
CASHMERE, WA / ACCESS Newswire / April 17, 2026 / Cashmere Valley Bank (OTCQX:CSHX) (the "Bank"), today announced the preliminary results of its previously declared cash tender offer for shares of its common stock, which expired at 5:00 p.m., Cashmere, Washington time, on Thursday, April 16, 2026.
Infinity Natural Resources Announces First Quarter Impact of Derivative Contracts
MORGANTOWN, W.Va.--(BUSINESS WIRE)--Infinity Natural Resources, Inc. (“Infinity” or the “Company”) (NYSE: INR) today provided an update on the impact of derivative contracts for the first quarter 2026. Impact of Derivative Contracts For the quarter ended March 31, 2026, Infinity recognized realized losses associated with settled derivative contracts of approximately $18 million. These results reflect cash settlements tied to financial contracts referencing crude oil prices, natural gas prices,...
Medicure Announces Resignation of President and Chief Operating Officer
WINNIPEG, MB / ACCESS Newswire / April 17, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported that Dr. Neil Owens has resigned as President and Chief Operating Officer, effective on or before May 31, 2026. Dr. Albert D...
Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development
VANCOUVER, BC / ACCESS Newswire / April 17, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H) (WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce the appointments of Dr. Islam Mohamed as Chief Medical Officer (CMO) and Stephen M. Novak as Chief of Research and Development (R&D)...
Grupo Aeroportuario del Pacifico Announces Filing of 2025 Annual Report and Form 20-F
GUADALAJARA, Mexico, April 17, 2026 (GLOBE NEWSWIRE) -- Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) today announced the filing of its annual report, corresponding to the year ended December 31, 2025, to the Mexican National Banking and Securities Commission (“CNBV”), the Mexican Stock Exchange (“BMV”), and the Institutional Stock Market Exchange (“BIVA”), as well as the filling of its Form 20-F to the U.S. Securities and Exchange Commission (“the SEC”)...
Ibero Announces Closing of Non-Brokered Private Placement of Units
VANCOUVER, British Columbia, April 17, 2026 (GLOBE NEWSWIRE) -- Ibero Mining Corp. (TSX.V:IMC) (OTCQB:AUCCF) (“Ibero” or the “Company”) is pleased to announce that, further to its news releases dated February 12, 2026 and March 30, 2026, and further to the partial revocation order granted by the British Columbia Securities Commission (“BCSC”) on February 11, 2026, and variation orders granted by the BCSC on February 11, 2026, March 19, 2026 and March 27, 2026 (collectively, the “Partial Revocation Order”), it has closed the non-brokered private placement by the issuance of 16,666,667 units in the capital of the Company (“Units”) at a price of $0.03 per Unit for aggregate gross proceeds of $500,000. Each Unit consists of one common share of the Company (“Common Share”) and one common share purchase warrant entitling the holder to purchase one Common Share at an exercise price of $0.08 for a period of thirty-six months from the closing date (the “Private Placement”)...
Five Star Bancorp Declares First Quarter Cash Dividend
RANCHO CORDOVA, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Five Star Bancorp (Nasdaq: FSBC) (“Five Star” or the “Company”), a holding company that operates through its wholly owned banking subsidiary, Five Star Bank (the "Bank"), announced today the declaration of a cash dividend of $0.25 per share on the Company's voting common stock. The dividend is expected to be paid on May 11, 2026, to shareholders of record as of May 4, 2026...
Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 2,222,223 shares of its common stock (or pre-funded warrants in lieu thereof), Series I warrants to purchase up to...
Terra Innovatum Provides Update on Annual Report Filing Process
NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Terra Innovatum Global N.V. (NASDAQ: NKLR) (“Terra” or the “Company”), developer of the SOLO™ Micro-Modular Reactor, today disclosed receipt of a Nasdaq Listing Delinquency Letter and provided an update on the timing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025...
AllianceBernstein National Municipal Income Fund, Inc. and AllianceBernstein Global High Income Fund, Inc. Announcement Regarding Planned Merger of Equitable and Corebridge
NEW YORK, April 17, 2026 /PRNewswire/ -- On March 26, 2026, Equitable Holdings, Inc. ("EQH"), the holder of a majority of the partnership interests in AllianceBernstein L.P. (the "Adviser"), the investment adviser to AllianceBernstein Global High Income Fund, Inc. (NYSE: AWF) and AllianceBernstein National Municipal Income Fund, Inc. (NYSE: AFB) (each a "Fund" and collectively, the "Funds"), and the indirect parent of AllianceBernstein Corporation, the general partner of the Adviser, and Corebridge Financial, Inc. ("Corebridge") announced that they have entered into a definitive agreement to merge (the "Transaction")...
Trade Desk Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of The Trade Desk, Inc. - TTD
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into The Trade Desk, Inc. (“Trade Desk” or the “Company”) (NasdaqGM: TTD). On February 12, 2025, the Company announced its financial results for the fourth quarter and full year of 2024, disclosing 4Q 2024 revenue of $741 million - below its previously issued guidance of $756...
Sharp Therapeutics Corp. Announces Fourth Quarter 2025 Results, Closing of Convertible Note Offering and Adoption of Semi-Annual Reporting
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 17, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its annual audited consolidated financial statements for the year ended December 31, 2025, and related management discussion and analysis ("MD&A") and annual information form. All dollar figures are in United States dollars, unless otherwise stated...
Fortinet Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fortinet Inc. - FTNT
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Fortinet Inc. (the “Company”) (NasdaqGS: FTNT). On August 6, 2025, the Company disclosed disappointing second-quarter 2025 financial results, including that it was already “approximately 40% to 50% of the way through the 2026 upgrade cycle at the end of the second qu...